Lund Stem Cell Center's Groundbreaking Entry into Pan-European Brain Research Collaboration

The Lund Stem Cell Center at Lund University in Sweden has announced its participation in the newly launched VISI-ON-BRAIN project, a €4.5 million Horizon Europe-funded Marie Skłodowska-Curie Doctoral Network. This initiative marks a significant advancement for European higher education institutions in stem cell research, uniting top universities and research centers across eight countries to pioneer advanced human brain models. Horizon Europe, the European Union's flagship research and innovation program running from 2021 to 2027, supports such collaborative efforts to address pressing health challenges like neurodegenerative diseases.

With brain disorders affecting one in three Europeans and costing the continent billions annually in healthcare and lost productivity, this network represents a strategic investment in next-generation neuroscience. Lund's involvement underscores Sweden's leadership in regenerative medicine, building on the center's legacy of over 300 researchers across 45 groups focused on translating stem cell discoveries into clinical therapies.

Established in 2003, the Lund Stem Cell Center has achieved milestones such as developing rapid methods for generating functional astrocytes from stem cells and securing major grants like the €8.3 million RAMP-UP doctoral program for advanced therapy medicinal products (ATMPs). This new collaboration positions Lund at the forefront of efforts to create human-relevant models, reducing reliance on animal testing and accelerating drug discovery for conditions like Alzheimer's and Parkinson's.

Unpacking VISI-ON-BRAIN: Objectives and Scope of the €4.5M Initiative

VISI-ON-BRAIN, or Cutting-edge Human In Vitro and In Silico Biomedical Tools on Brain Disorders, aims to bridge the translational gap in neuroscience. Traditional animal models often fail to predict human responses, contributing to high drug failure rates—over 90% for neurodegenerative therapies. The project develops in vitro (lab-grown cell-based) and in silico (computational) models to generate more reliable data for preclinical testing.

Running from 2026 to 2029, it will train 15 doctoral researchers through interdisciplinary PhD projects. These early-career scientists will gain skills in bioengineering, data science, and regulatory science, with mandatory secondments in industry and clinics. Coordinated by the University of Barcelona's Creatio center under Prof. Josep M. Canals, the network emphasizes New Approach Methodologies (NAMs)—innovative, non-animal tools endorsed by the EU to meet ethical and scientific demands.

Expected outcomes include validated brain models for Alzheimer's, Parkinson's, and Huntington's disease, improved decision-making in drug development, and policy recommendations for regulatory acceptance of NAMs. This aligns with Europe's push to reduce animal use, as outlined in the European Commission's roadmap for ethical research.

A Consortium of Excellence: Universities and Partners Driving Innovation

The VISI-ON-BRAIN consortium boasts 15 partners, blending academia, clinics, and industry for a holistic approach. Beneficiaries include Lund University (Sweden), University of Barcelona (Spain), Technical University of Denmark (DTU), Eberhard Karls University Tübingen (Germany), Cardiff University and King's College London (UK), Italy's National Research Council (CNR), and private firms like Starlab Barcelona and FRESCI (Spain). Associated partners such as Utrecht University (Netherlands), University of Milan-Bicocca (Italy), Verigraft AB (Sweden), and the European Commission's Joint Research Centre add clinical and regulatory expertise.

• University of Barcelona (Coordinator): Leads in vitro modeling and NAM validation.
• Lund University: Provides stem cell expertise for neural organoids.
• DTU (Denmark): Focuses on computational in silico tools.
• Prinses Máxima Centre (Netherlands): Contributes pediatric oncology insights for brain models.
• Tübingen University (Germany): Advances bioengineering of complex tissues.

This pan-European setup fosters knowledge exchange, vital for higher education where cross-border mobility enhances PhD training. For students eyeing research jobs in Europe, such networks offer unparalleled exposure.

Lund's Stellar Contributors: Ahlenius and Falk Lead the Charge

At Lund, Associate Prof. Henrik Ahlenius heads the Stem Cells, Aging, and Neurodegeneration group. His work targets glial cell roles in Alzheimer's initiation, using CRISPR-edited stem cells to model disease progression. Recent publications include studies on astrocyte dysfunction in frontotemporal dementia and microglia in aged brains, highlighting how non-neuronal cells drive neurodegeneration.

Prof. Anna Falk, director of Lund's ATMP Centre, specializes in neural stem cells from induced pluripotent stem cells (iPSCs)—adult cells reprogrammed to an embryonic-like state. Her lab creates neuroepithelial stem (NES) cells and 3D brain organoids to dissect neurodevelopmental disorders. Falk's research bridges basic science and GMP-compliant therapies, with key papers on single-cell analysis of iPSC-derived progenitors.

Quote from Ahlenius: "New and better models are needed to improve efficiency in developing new drugs for neurodegenerative diseases." Their labs exemplify how university research fuels EU consortia.

Demystifying Brain Organoids: Step-by-Step from Stem Cells to Mini-Brains

Brain organoids are 3D structures grown from iPSCs that mimic human brain architecture, offering a window into development and disease absent in 2D cultures or animals. Here's the process:

1. Reprogramming: Skin fibroblasts from patients are reprogrammed to iPSCs using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc).
2. Neural Induction: iPSCs form neural rosettes, precursors to neuroepithelial stem cells.
3. Organoid Formation: Aggregates self-organize into layered structures with neurons, glia, and vasculature over months.
4. Maturation and Perturbation: Models are diseased via gene edits or drugs to study pathology.
5. Integration: Advanced setups fuse organoids (assembloids) or add computational layers for in silico predictions.

Europe leads here, with Lund's models replicating glial-neuron interactions key to Alzheimer's. Challenges like vascularization are being addressed via bioengineering.

Combating Europe's Neurodegenerative Crisis: Stats and Stakes

Neurodegenerative diseases burden Europe heavily: Alzheimer's affects 10 million, Parkinson's 1.5 million, with prevalence rising 20% by 2030 due to aging populations. Costs exceed €250 billion yearly for dementia alone, per EU reports. Drug discovery fails often—95% of Alzheimer's candidates flop—due to animal model mismatches in genetics and pathology.

VISI-ON-BRAIN targets these via patient-specific models, promising personalized medicine. In Sweden, Lund's MultiPark center tackles Parkinson's, aligning with national priorities.

Stakeholder views: Regulators like EMA push NAMs; industry seeks faster pipelines; patients advocate ethical alternatives.

EU's Ethical Shift: NAMs and the Decline of Animal Testing in Neuroscience

The EU aims to phase out animal testing where possible, promoting NAMs like organoids and AI simulations. VISI-ON-BRAIN aligns with this, validating models for regulatory use. Limitations of rodents: shorter lifespans miss late-onset diseases; genetic differences skew results.

Progress: Organoids predict toxicity better; in silico tools analyze big data. Impacts: Fewer animals (EU uses 10M yearly), faster R&D, cost savings (€100M+ per failed trial).

Empowering Future Scientists: Doctoral Training in Europe's Top Labs

As a Marie Skłodowska-Curie network, VISI-ON-BRAIN recruits 15 PhDs for intersectoral training—academia to industry. Benefits: Mobility across countries, transferable skills, networks for careers. For Europe's universities, it boosts competitiveness, attracting talent amid brain drain concerns.

Similar to Lund's RAMP-UP (21 PhDs), it emphasizes ATMPs. Aspiring researchers: Check postdoc opportunities and scholarships in stem cells.

Implications for Higher Education: Fostering Innovation and Careers

This network exemplifies EU-funded higher ed excellence, integrating research, teaching, and industry. Universities gain funding, prestige; students access cutting-edge facilities. Broader: Addresses skills gaps in biotech, with 300K jobs needed by 2030.

Cultural context: Sweden's strong welfare supports risky research; Barcelona's biotech hub accelerates translation. Actionable: Pursue academic CV tips for applications.

Photo by Logan Voss on Unsplash

Looking Ahead: Transforming Drug Discovery and Patient Outcomes

By 2029, VISI-ON-BRAIN could yield validated models slashing development timelines 30-50%, per NAM studies. Future: Assembloids for circuit-level diseases; AI integration for precision medicine. For Europe, it's a model for collaborative higher ed tackling global health crises.

Explore higher ed jobs, rate professors, or university positions in neuroscience. Lund exemplifies opportunity in stem cell research.